Payment overview · 2025
General Payments
$154.12
12 reported records · 2 companies
Healthcare provider profile · identity verified
Stacy Siegendorf, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW ORLEANS, LA · NPI 1336180785
Verified facts
What the public records show
CMS Open Payments records show Stacy Siegendorf, MD received $154.12 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 90.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $140.13 | 90.9% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.99 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $154.12 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $140.13 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $140.13 | 11 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 128 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
128 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 610 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 588 | 170 |
| Levothyroxine Sodium | Levothyroxine Sodium | 470 | 116 |
| Losartan Potassium | Losartan Potassium | 470 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 375 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 326 | 94 |
| Gabapentin | Gabapentin | 312 | 101 |
| Eliquis | Apixaban | 256 | 50 |
| Omeprazole | Omeprazole | 255 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 70 |
| Metformin Hcl | Metformin Hcl | 184 | 63 |
| Carvedilol | Carvedilol | 178 | 53 |
| Simvastatin | Simvastatin | 151 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 43 |
| Furosemide | Furosemide | 129 | 40 |
| Irbesartan | Irbesartan | 129 | 34 |
| Ozempic | Semaglutide | 128 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 49 |
| Alprazolam | Alprazolam | 126 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 42 |
| Potassium Chloride | Potassium Chloride | 124 | 39 |
| Spironolactone | Spironolactone | 119 | 33 |
| Alendronate Sodium | Alendronate Sodium | 115 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 31 |
| Mirtazapine | Mirtazapine | 112 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 45 |
| Januvia | Sitagliptin Phosphate | 105 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 27 |
| Ezetimibe | Ezetimibe | 100 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 38 |
| Glimepiride | Glimepiride | 94 | 29 |
| Atenolol | Atenolol | 91 | 22 |
| Valsartan | Valsartan | 89 | 30 |
| Lorazepam | Lorazepam | 85 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 84 | 29 |
| Memantine Hcl | Memantine Hcl | 80 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 24 |
| Sertraline Hcl | Sertraline Hcl | 76 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 24 |
| Donepezil Hcl | Donepezil Hcl | 71 | 13 |
| Mounjaro | Tirzepatide | 70 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 57 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 13 |
| Allopurinol | Allopurinol | 65 | 23 |
| Prednisone | Prednisone | 65 | 52 |
| Trazodone Hcl | Trazodone Hcl | 65 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 20 |
| Candesartan Cilexetil | Candesartan Cilexetil | 54 | 15 |
| Estradiol | Estradiol | 54 | 24 |
| Montelukast Sodium | Montelukast Sodium | 54 | 17 |
| Bupropion Xl | Bupropion Hcl | 53 | 13 |
| Jardiance | Empagliflozin | 53 | 11 |
| Ketoconazole | Ketoconazole | 52 | 27 |
| Azithromycin | Azithromycin | 51 | 40 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 47 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 41 |
| Topiramate | Topiramate | 45 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Fluconazole | Fluconazole | 44 | 31 |
| Ibandronate Sodium | Ibandronate Sodium | 44 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Pregabalin | Pregabalin | 43 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 18 |
| Metformin Hcl Er | Metformin Hcl | 42 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | 12 |
| Tramadol Hcl | Tramadol Hcl | 39 | suppressed |
| Lisinopril | Lisinopril | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Linzess | Linaclotide | 37 | 13 |
| Meloxicam | Meloxicam | 36 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 15 |
| Amoxicillin | Amoxicillin | 33 | 30 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 33 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 33 | 11 |
| Finasteride | Finasteride | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 14 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 26 |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 16 |
| Levofloxacin | Levofloxacin | 28 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 18 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Terconazole | Terconazole | 14 | 11 |
| Cephalexin | Cephalexin | 13 | 12 |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $154.12 · 12 records | Novo Nordisk Inc | Ozempic, Rybelsus, The Cologuard Plus Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error